A study of vedolizumab for the treatment of moderate to severe active ulcerative colitis (UC)

Trial Profile

A study of vedolizumab for the treatment of moderate to severe active ulcerative colitis (UC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 May 2017 New trial record
    • 08 May 2017 Results published in the Takeda Pharmaceuticals media release.
    • 08 May 2017 According to a Takeda Pharmaceutical media release, cohort analysis of this trial from the U.S. VICTORY (Vedolizumab for Health OuTComes in InflammatORY Bowel Diseases) consortium was presented at the 2017 Digestive Disease Week (DDW) annual scientific meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top